Viewing nowPregabalin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Myungmoon Pharmaceutical Co., Ltd.

MFDS item code 201603601 · Approved 2016.06.20 · Insurance code 649807180
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults and is used as an adjunct for partial seizures in patients with epilepsy. It is also effective in treating fibromyalgia. In summary, this drug is used for neuropathic pain, epilepsy, and fibromyalgia.
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. This medicine is primarily excreted by the kidneys, so the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be started at 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be started at 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose is an additional dose administered once. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, you must inform your healthcare provider immediately if you experience mood changes or depressive symptoms while taking this medication. Patients with hypersensitivity to this drug or those with certain genetic disorders such as lactose intolerance should not take it. Diabetic patients should be cautious as weight gain may require dosage adjustments of blood sugar control medications. If symptoms of angioedema occur, discontinue use immediately and consult your healthcare provider. Elderly patients may experience increased dizziness and drowsiness, increasing their risk of falls; hence, extra caution is advised especially during the initial dosing. There may be symptoms of blurred vision or eye abnormalities; consult your healthcare provider if such symptoms occur. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, headaches, nausea, and anxiety; therefore, consult your healthcare provider to gradually discontinue use. Patients with a history of substance abuse may have a higher risk of abuse with this medication and should be particularly cautious while taking it. Patients with heart disease or impaired kidney function should consult their healthcare provider before taking this medication as dosage adjustment may be needed. This medication can cause drowsiness and dizziness, so avoid driving or operating dangerous machinery until symptoms are established. In early pregnancy, there may be a risk of fetal malformation; thus, women who are pregnant or planning to become pregnant should consult before use. Lactating women should discuss with their healthcare provider whether to discontinue breastfeeding or the medication since it can be transmitted through breast milk. Overdose may present with drowsiness, confusion, depression, etc., and treatment such as dialysis may be needed if necessary. Keep this medication out of reach of children, and it is advisable not to transfer it to another container. Severe skin reactions can occur rarely with this medication, so if you experience skin rashes, swelling, fever, or similar symptoms, discontinue use immediately and consult your healthcare provider.
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly sealed container to prevent air and moisture exposure. It's best to maintain storage temperature between 15 to 30 degrees Celsius.
A hard capsule with a reddish-brown upper part and a white lower part filled with a white powder that is white or pale yellow in color.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Myungmoon Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.